数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

股本结构

单位:万股
公告日期 2024-01-16 2023-11-07 2023-08-10 2023-05-11 2023-03-23 2023-01-30
证券总股本 2077.25 2076.24 2074.96 2074.18 2074.18 2072.69
普通股本 2077.25 2076.24 2074.96 2074.18 2074.18 2072.69
优先股 未披露 未披露 未披露 未披露 未披露 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2024-01-12 2023-09-30 2023-06-30 2023-03-31 2023-03-16 2023-01-19
注释:中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本(万股) 变动后优先股(万股) 变动原因 变动日期
2024-01-16 2077.25 未披露 定期报告 2024-01-12
2023-11-07 2076.24 未披露
更多>>
From June 30, 2023 to September 30, 2023 Release of restricted stock units
2023-09-30
2023-08-10 2074.96 未披露
更多>>
From March 31, 2023 to June 30, 2023 Release of restricted stock units
2023-06-30
2023-05-11 2074.18 未披露
更多>>
From December 31, 2022 to March 31, 2023 Release of restricted stock units
2023-03-31
2023-03-23 2074.18 未披露 定期报告 2023-03-16
2023-01-30 2072.69 未披露 定期报告 2023-01-19
2023-01-17 2072.69 未披露
更多>>
Eargo, Inc. (“Eargo” or the “Company”) (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced that it has filed a Certificate of Amendment (the “Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the previously announced 1-for-20 reverse stock split of the Company’s common stock (the “Reverse Stock Split”).
2023-01-18
2022-12-19 41453.86 未披露 定期报告 2022-12-07
2022-11-07 3941.11 未披露
更多>>
From June 30, 2022 to September 30, 2022 Exercise of stock options and release of restricted stock units
2022-09-30
2022-09-13 3941.10 未披露 定期报告 2022-09-06
2022-08-08 3938.54 未披露
更多>>
From March 31, 2022 to June 30, 2022 Exercise of stock options and release of restricted stock units
2022-06-30
2022-05-24 3935.86 未披露 定期报告 2022-05-19
2022-05-13 3935.49 未披露 定期报告 2022-05-04
2022-05-24 3934.45 未披露
更多>>
From December 31, 2021 to March 31, 2022 Exercise of stock options
2022-03-31
2022-05-13 3930.71 未披露
更多>>
From December 31, 2020 to December 31, 2021 Exercise of stock options and release of restricted stock units Issuance of common stock in connection with employee stock purchase plan
2021-12-31
2022-05-13 3927.04 未披露
更多>>
From June 30, 2021 to September 30, 2021 Exercise of stock options and release of restricted stock units
2021-09-30
2021-09-24 3926.29 未披露 定期报告 2021-09-14
2021-08-12 3916.04 未披露 定期报告 2021-08-06
2021-08-12 3914.16 未披露
更多>>
From March 31, 2021 to June 30, 2021 Exercise of stock options and release of restricted stock units Issuance of common stock in connection with employee stock purchase plan
2021-06-30
2021-05-13 3873.15 未披露 定期报告 2021-05-05
2021-05-13 3829.81 未披露
更多>>
From December 31, 2020 To March 31, 2021 Exercise of stock options
2021-03-31
2021-03-16 3829.54 未披露 定期报告 2021-03-08
2021-03-16 3824.66 未披露
更多>>
From December 31, 2019 to December 31, 2020 Issuance of Series E convertible preferred stock, net of issuance costs of $4,056 Issuance of Series E convertible preferred stock, upon extinguishment of convertible notes Conversion of convertible preferred stock to public offering Issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs of $14,031 Exercise of common stock warrants Exercise of stock options
2020-12-31
2020-11-20 3818.65 未披露 定期报告 2020-11-18
2020-10-19 3632.87 未披露
更多>>
1.Common stock offered by the company 7,851,852 shares. 2.The number of shares of common stock to be outstanding after this offering reflected in the table above is based on 28,476,854 shares of common stock outstanding as of June 30, 2020
2020-10-16
From June 30, 2023 to September 30, 2023 Release of restricted stock units
From March 31, 2023 to June 30, 2023 Release of restricted stock units
From December 31, 2022 to March 31, 2023 Release of restricted stock units
Eargo, Inc. (“Eargo” or the “Company”) (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced that it has filed a Certificate of Amendment (the “Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the previously announced 1-for-20 reverse stock split of the Company’s common stock (the “Reverse Stock Split”).
From June 30, 2022 to September 30, 2022 Exercise of stock options and release of restricted stock units
From March 31, 2022 to June 30, 2022 Exercise of stock options and release of restricted stock units
From December 31, 2021 to March 31, 2022 Exercise of stock options
From December 31, 2020 to December 31, 2021 Exercise of stock options and release of restricted stock units Issuance of common stock in connection with employee stock purchase plan
From June 30, 2021 to September 30, 2021 Exercise of stock options and release of restricted stock units
From March 31, 2021 to June 30, 2021 Exercise of stock options and release of restricted stock units Issuance of common stock in connection with employee stock purchase plan
From December 31, 2020 To March 31, 2021 Exercise of stock options
From December 31, 2019 to December 31, 2020 Issuance of Series E convertible preferred stock, net of issuance costs of $4,056 Issuance of Series E convertible preferred stock, upon extinguishment of convertible notes Conversion of convertible preferred stock to public offering Issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs of $14,031 Exercise of common stock warrants Exercise of stock options
1.Common stock offered by the company 7,851,852 shares. 2.The number of shares of common stock to be outstanding after this offering reflected in the table above is based on 28,476,854 shares of common stock outstanding as of June 30, 2020